5 Reasons Biogen’s Shares Have Dropped 36% in 2024
Nov 13, 2024 · A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a few of the factors that have sent Biogen's shares down this year.
Biogen to Realign Resources for Alzheimer's Disease Franchise
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area expected to drive near and long-term growth.
News - Biogen
Biogen News Releases and Company Statements. Media Contacts. US Media Relations. [email protected]. Europe Media Relations. [email protected]. Japan Media Relations. [email protected]. Filter by: January 7, 2025 Biogen to Present at the 43rd Annual J.P. Morgan Healthcare Conference ...
Biogen Inc. (BIIB) Latest Stock News & Headlines - Yahoo Finance
Get the latest Biogen Inc. (BIIB) stock news and headlines to help you in your trading and investing decisions.
Biogen discontinues Alzheimer’s medication Aduhelm - CNN
Jan 31, 2024 · The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the company...
Biogen Bolsters Late-Stage Pipeline, Expands Immunology …
May 22, 2024 · Proposed acquisition builds on Biogen capabilities in immunology with plans to combine Human Immunology Biosciences expertise in immune-mediated indications with Biogen’s global development and commercial experience in rare diseases
Biogen to Realign Resources for Alzheimer's Disease Franchise
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area...
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, …
Feb 23, 2024 · If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).
Biogen Continues 24% Sprint On Twist In Alzheimer's Treatment
May 15, 2024 · Biogen (BIIB) stock jumped early Wednesday after the Food and Drug Administration gave its Eisai (ESAIY)-partnered Alzheimer's treatment a fast-track designation. The companies are submitting...
Biogen (BIIB) Raises Forecast as Alzheimer’s Drug Leqembi Shows …
Oct 30, 2024 · Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new...
- Some results have been removed